Revolution Medicines counsel sells 3,366 shares

RVMD’s SVP & General Counsel sold 3,366 shares under a Rule 10b5-1 plan to cover tax withholding on vested restricted stock units.

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) disclosed that SVP & General Counsel Jeff Cislini sold a total of 3,366 shares of common stock on September 16, 2026 in open-market transactions, consisting of 52 shares at a weighted average price of $195.01 and 3,314 shares at a weighted average price of $199.30. The sales were made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy tax withholding obligations upon the vesting of restricted stock units, and following these transactions his holdings include 37,088 restricted stock units. Each trade was executed in multiple lots within the disclosed price ranges.

Insider Trade Summary 10b5-1

Net Seller: 3,366 shares

Net Sell 2 txns

Insider Cislini Jeff

Role SVP & General Counsel

Sold 3,366 shs ($671K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	52	$195.0087	$10K
Sale	Common Stock F1, F3	3,314	$199.3032	$660K

Holdings After Transaction: Common Stock — 52,541 shares (Direct)

Footnotes (3)

1. F1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.
2. F2. The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. F3. Includes 37,088 restricted stock units.

Key Figures

Shares sold (first transaction): 52 shares Weighted average sale price (first transaction): $195.01 per share Shares sold (second transaction): 3,314 shares +4 more

7 metrics

Shares sold (first transaction) 52 shares Common stock sold on September 16, 2026

Weighted average sale price (first transaction) $195.01 per share Executed in trades from $195.00 to $195.03

Shares sold (second transaction) 3,314 shares Common stock sold on September 16, 2026

Weighted average sale price (second transaction) $199.30 per share Weighted average for multiple trades

Total shares sold 3,366 shares Aggregate of both reported sales on September 16, 2026

Restricted stock units included in holdings 37,088 restricted stock units Equity awards included in post-transaction holdings

Rule 10b5-1 plan adoption date May 31, 2023 Instruction letter used for these sales

Key Terms

Rule 10b5-1 instruction letter, restricted stock units, weighted average sale price, tax withholding obligation

4 terms

Rule 10b5-1 instruction letter regulatory

"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted"

restricted stock units financial

"Includes 37,088 restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The price reported in Column 4 above reflects the weighted average sale price."

tax withholding obligation financial

"to satisfy the Reporting Person's tax withholding obligation upon the vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider sale did RVMD report for SVP & General Counsel Jeff Cislini?

RVMD reported that Jeff Cislini sold 3,366 shares of common stock on September 16, 2026 in open-market transactions, executed in multiple trades at specified price ranges, as disclosed in the Form 4.

At what prices were the RVMD shares sold in this Form 4?

The Form 4 shows 52 RVMD shares sold at a $195.01 weighted average price (trades from $195.00 to $195.03) and 3,314 shares sold at a $199.30 weighted average price, with prices detailed in the filing’s described ranges.

Was the RVMD insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the reporting person’s tax withholding obligation upon vesting of restricted stock units.

How many shares did the RVMD insider sell in total on September 16, 2026?

The reporting person sold a total of 3,366 shares of Revolution Medicines common stock on September 16, 2026, combining 52 shares from one transaction and 3,314 shares from another.

What RVMD equity awards are reported as held after these transactions?

A footnote states that the reporting person’s position includes 37,088 restricted stock units after the reported sales. These RSUs are part of his remaining equity holdings.

Who is the insider involved in the RVMD Form 4 and what is his role?

The Form 4 relates to Jeff Cislini, who is identified as SVP & General Counsel of Revolution Medicines, Inc. He is the reporting person for the disclosed transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 06:01 PM Accepted by SEC EDGAR 09/18/2026 - 06:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cislini Jeff

(Last) (First) (Middle)

REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2026		S(1)		52	D	$195.0087(2)	55,855	D
Common Stock	09/16/2026		S(1)		3,314	D	$199.3032	52,541(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.

2. The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. Includes 37,088 restricted stock units.

	/s/ Jack Anders, as Attorney-in-fact for Jeff Cislini	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)